Dr. Zeynep Eroglu, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 189
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
FL license ME124552
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- H Lee Moffitt Cancer Ctr and Res Inst Life Time Cancer Scrn Ctr Inc (1,178 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 287
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 139 | 107 |
| Established patient office or other outpatient visit, 40-54 minutes | 105 | 80 |
| New patient office or other outpatient visit, 60-74 minutes | 60 | 60 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Tampa, FL | 30 |
| Mektovi (binimetinib) | 13 |
| Braftovi (encorafenib) | 13 |
| Mekinist (trametinib dimethyl sulfoxide) | 13 |
| Tramadol Hcl Other prescribers in Tampa, FL | 12 |
| Dexamethasone Other prescribers in Tampa, FL | 11 |
| Hydrocortisone Other prescribers in Tampa, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 6 payments worth $694 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $189 |
|---|---|
| Sun Pharmaceutical Industries Inc. | $151 |
| Pfizer Inc. | $135 |
| Regeneron Pharmaceuticals, Inc. | $116 |
| Iovance Biotherapeutics, Inc. | $84.91 |
| Regeneron Healthcare Solutions, Inc. | $17.02 |
| Food and Beverage | $676 |
|---|---|
| Education | $17.02 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Feb 21, 2025 | Education LIBTAYO · ONCOLOGY · in-kind | $17.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $3,342,710 in research payments for these studies, mostly to the institutions running them.
- A randomized pilot trial of adjuvant therapy based on pathologic response after neoadjuvant encorafenib and binimetinib in advanced melanoma
Pfizer Inc. - A phase 1AB openlabel master study of PF07799544 as a singleagent and in combination with other targeted agents in participants with advanced solid tumors
Pfizer Inc. - Phase 2 study of afatinib in advanced cutaneous squamous cell carcinoma
Boehringer Ingelheim Pharmaceuticals, Inc. - A randomized pilot trial of adjuvant therapy based on pathologic response after neoadjuvant encorafenib and binimetinib in advanced melanoma
Array Biopharma Inc - A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
E.r. Squibb & Sons, L.l.c. - Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716
Merck Sharp & Dohme LLC - Adaptive vismodegib therapy in advanced basal cell carcinoma
Genentech, Inc. - A phase 1 dose escalation and cohort expansion study of TSR-022, an an
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.